EchoIQ LimitedASX: EIQ

Exceptional Results from Validation Study for EchoSolv HF

· Issued by EchoIQ Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

EchoIQ Limited has completed a validation study for its heart failure detection software, EchoSolv HF, at the Mayo Clinic, achieving exceptional results in performance metrics. The study demonstrated a high sensitivity and specificity in detecting heart failure, exceeding the company's expectations. This completion marks the final clinical requirement before the company submits for FDA clearance, which is anticipated soon. The company plans to leverage its presence in the US market to promote EchoSolv HF following potential FDA approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

EchoIQ Limited on 6ix

Story so far

Earlier from EchoIQ

Later from EchoIQ

All EchoIQ news releases